2. Apoptosis
  3. Apoptosis
  4. DB2313

DB2313 is a potent inhibitor of transcription factor PU.1. DB2313 inhibits PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis in acute myeloid leukemia (AML) cells and has anticancer effects.

For research use only. We do not sell to patients.

CAS No. : 2170606-74-1

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
250 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of DB2313:

DB2313 Related Antibodies

Top Publications Citing Use of Products

    DB2313 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 4;16(1):7134.  [Abstract]

    DB2313 (660 nM) inhibited the transcription of CSF1R, CALM1, and SLC2A3 while promoting E2F in neutrophils.

    DB2313 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 4;16(1):7134.  [Abstract]

    DB2313 (17 mg/kg; i.p.) decreased serum levels of MMP9 and MPO/DNA‐NETs in the murine MI/RI model.

    DB2313 purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067.  [Abstract]

    DB2313 (0.3 mg; i.p.; once every 3 d) downregulated IL-9 expression and the proportions of Th9 cells in the spleen and PBMCs of collagen-induced arthritis (CIA) mice.

    DB2313 purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067.  [Abstract]

    PU.1 inhibitor DB2313 (0.3 mg; i.p.; once every 3 d) suppressed IL-9 release from Th9 cells of collagen-induced arthritis (CIA) mice.

    DB2313 purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067.  [Abstract]

    Effect of PU.1 inhibitor DB2313 (0.3 mg; i.p.; once every 3 d) on joint neovascularization in collagen-induced arthritis (CIA) mice.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    DB2313 is a potent inhibitor of transcription factor PU.1. DB2313 inhibits PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis in acute myeloid leukemia (AML) cells and has anticancer effects[1].

    IC50 & Target

    IC50: 14 nM (PU.1)[1]
    In Vitro

    DB2313 treatment leads to a profound decrease in the growth of PU.1 URE–/– acute myeloid leukemia (AML) cells (IC50 of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE–/– AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating[1].
    In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    DB2313 Related Antibodies
    In Vivo

    DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE–/– AML cells[1]
    Dosage: 17 mg/kg
    Administration: Intraperitoneal injection; three times per week; for 3 weeks
    Result: Decreased tumor burden and resulted in increased survival.
    Molecular Weight

    708.83

    Formula

    C42H41FN8O2
    CAS No.
    Appearance

    Solid

    Color

    Off-white to gray

    SMILES

    FC1=C(COC2=CC=C(C3=NC4=CC=C(C(NC(C)C)=N)C=C4N3)C=C2)C=CC=C1COC5=CC=C(C6=NC7=CC=C(C(NC(C)C)=N)C=C7N6)C=C5
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (141.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.4108 mL 7.0539 mL 14.1078 mL
    5 mM 0.2822 mL 1.4108 mL 2.8216 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 3.33 mg/mL (4.70 mM); Clear solution

      This protocol yields a clear solution of ≥ 3.33 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 3.33 mg/mL (4.70 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 3.33 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 5 mg/mL (7.05 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.4108 mL 7.0539 mL 14.1078 mL 35.2694 mL
    5 mM 0.2822 mL 1.4108 mL 2.8216 mL 7.0539 mL
    10 mM 0.1411 mL 0.7054 mL 1.4108 mL 3.5269 mL
    15 mM 0.0941 mL 0.4703 mL 0.9405 mL 2.3513 mL
    20 mM 0.0705 mL 0.3527 mL 0.7054 mL 1.7635 mL
    25 mM 0.0564 mL 0.2822 mL 0.5643 mL 1.4108 mL
    30 mM 0.0470 mL 0.2351 mL 0.4703 mL 1.1756 mL
    40 mM 0.0353 mL 0.1763 mL 0.3527 mL 0.8817 mL
    50 mM 0.0282 mL 0.1411 mL 0.2822 mL 0.7054 mL
    60 mM 0.0235 mL 0.1176 mL 0.2351 mL 0.5878 mL
    80 mM 0.0176 mL 0.0882 mL 0.1763 mL 0.4409 mL
    100 mM 0.0141 mL 0.0705 mL 0.1411 mL 0.3527 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    DB2313 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    DB23132170606-74-1DB 2313DB-2313ApoptosisPU.1DNAanticanceracutemyeloidleukemiaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    DB2313
    Cat. No.:
    HY-124629
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.